New IMI-Chairman looks to future
23.04.2012 - The Innovative Medicines Initiative (IMI), a €600m public-private partnership between 26 global pharma players and the European Commission, has a new Chairman.
At the beginning of March, Roch Doliveux, CEO of Brussels-headquartered UCB S.A., agreed to take the post. The Innovative Medicines Initiative (IMI) is an industry-led pre-competitive joint project aimed at overcoming current bottlenecks in the drug development process. Before joining UCB in 2003 and becoming the company’s CEO in 2005, Doliveux worked for Ciba-Geigy and Schering-Plough.